

Response to “Comment on ‘Cannabinoids in dermatologic surgery’”



To the Editor: We thank Fazzari et al¹ for their interest in our article² and for their comments. We agree that we were not able to fully discuss the extensive scope of all cannabinoids and their effects and we therefore appreciate that in their comments they emphasized the diversity of the cannabinoids and some of the distinguished effects of non-cannabidiol (CBD) cannabinoids.

We are grateful to Fazzari et al¹ for alerting us to a typographical error in the manuscript, where “cannabinoids” was unfortunately incorrectly replaced by “CBD.” The paragraph, “Therapeutic applications of CBD” should have been entitled “Therapeutic applications of cannabinoids” and the term “CBD” in that paragraph, in Fig 1, as well as in the sentence, “Further studies would be necessary to characterize the impact of the drug interactions of CBD on patient outcomes” should have been replaced by the word “cannabinoids.” We regret that we were not able to catch this editorial error earlier and the confusion that it caused.

We also read with much interest the reports on the use of topical cannabis-based medicines on wound closure and healing.^{3,4} This was also pointed out by Abdalla et al⁵ in their recent commentary. Based on the available preliminary data, we agree that topical cannabis-based medicines hold much potential and eagerly await the results of larger randomized trials in multiple types of wounds.

We wholeheartedly agree that both CBD and non-CBD cannabinoids hold significant promise for the treatment of dermatologic conditions, although for the purposes of our review, we focused primarily on implications for dermatologic surgery. At a minimum, we are excited about continued dialogue regarding this thrilling field of research and discovery and its impact on the field.

Ha Eun Kong, MD, PhD,^a and Travis W. Blalock, MD^{a,b,c}

From the Department of Dermatology,^a and Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia,^b and Atlanta VA Health System, Decatur, Georgia.^c

Funding sources: None.

IRB approval status: Not applicable.

Correspondence and reprint requests to: Travis W. Blalock, MD, Emory Clinic Department of Dermatology, 1525 Clifton Road, Atlanta, GA 30322

E-mail: twblalo@emory.edu

Conflicts of interest

None disclosed.

REFERENCES

1. Fazzari FGT, Maida V. Comment on “Cannabinoids in dermatologic surgery”. *J Am Acad Dermatol*. 2021;85:e409-e410. <https://doi.org/10.1016/j.jaad.2021.05.074>
2. Kong HE, Pollack BP, Blalock TW. Cannabinoids in dermatologic surgery. *J Am Acad Dermatol*. 2021;85:1565-1570. <https://doi.org/10.1016/j.jaad.2021.01.016>
3. Maida V, Shi RB, Fazzari FGT, Zomparelli L. Topical cannabis-based medicines — a novel paradigm and treatment for non-uremic calciphylaxis leg ulcers: an open label trial. *Int Wound J*. 2020;17(5):1508-1516. <https://doi.org/10.1111/IWJ.13484>
4. Maida V, Shi RB, Fazzari FGT, Zomparelli LM. A new treatment paradigm for sickle cell disease leg ulcers: topical cannabis-based medicines. *Exp Dermatol*. 2021;30(2):291-293. <https://doi.org/10.1111/EXD.14256>
5. Abdalla T, Lytvyn Y, McDonald KA, Mufti A, Alavi A. A response to “Cannabinoids in Dermatologic Surgery”: the added considerations of factors affecting tissue perfusion, wound healing, and modes of administration in safety and efficacy of cannabinoids. *J Am Acad Dermatol*. 2021;85:e385-e386. <https://doi.org/10.1016/j.jaad.2021.04.068>

<https://doi.org/10.1016/j.jaad.2021.08.015>